Physician profile
Chris Mcgee
NPI 1487659439
$6,365.72
in general payments reported to CMS, 2019-2025
50 companies · $606 in 2025
The $606 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $915 · 2020: $873 · 2021: $1,085 · 2022: $1,031 · 2023: $1,204 · 2024: $652 · 2025: $606.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,462.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,461.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $959.05 | 2019-2025 | Farxiga, Breztri, Evusheld |
| Abbvie INC. | $874.63 | 2021-2025 | |
| Allergan, INC. | $415.89 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $374.02 | 2019-2023 | Jardiance |
| Novo Nordisk INC | $308.58 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Mimedx Group, INC. | $283.54 | 2024-2025 | |
| Astellas Pharma US INC | $279.24 | 2019-2023 | Veozah |
| Pfizer INC. | $273.38 | 2019-2025 | |
| Lilly USA, LLC | $262.57 | 2019-2025 | Mounjaro, Zepbound |
| Abbott Laboratories | $232.67 | 2021-2025 | Freestyle Libre 3, Proclaim, Aveir |
| Gm Pharmaceuticals, INC. | $165.10 | 2022 | |
| Corcept Therapeutics | $164.66 | 2023-2025 | Korlym |
| Glaxosmithkline, LLC. | $142.55 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Amarin Pharma, INC. | $141.38 | 2019-2020 | |
| Daiichi Sankyo INC. | $124.10 | 2019-2021 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chris Mcgee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.